KURA

Kura Oncology, Inc. [KURA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

KURA Stock Summary

Top 10 Correlated ETFs

KURA


Top 10 Correlated Stocks

KURA


In the News

07:30 28 Mar 2024 KURA

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:

07:30 28 Mar 2024 KURA

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

08:41 28 Mar 2024 KURA

Kura Oncology stock jumped another 20% on Tuesday: here's why

Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive preliminary data for a Phase 1 study of its Ziftomenib “in combination with standards of care”. Ziftomenib trial pushes Kura Oncology stock up The dose-escalation trial studied the combination in patients of acute myeloid leukemia.

03:32 28 Mar 2024 KURA

Kura Oncology: Riding The Menin Hype Wave In AML Therapy

Kura Oncology is an oncology-focused biotech developing targeted therapies for various forms of cancer with high unmet need. Their pipeline includes ziftomenib for AML, with promising phase 2 results and a potential data readout in 2024. They are also developing tipifarnib for HRAS-mutated HNSCC, with breakthrough therapy designation and positive response rates in early trials.

07:30 28 Mar 2024 KURA

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences.

04:05 28 Mar 2024 KURA

Kura Oncology to Report Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the close of U.S. financial markets on Thursday, November 2, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

01:31 28 Mar 2024 KURA

What Makes Kura Oncology (KURA) a New Buy Stock

Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

04:40 28 Mar 2024 KURA

Kura's Ziftomenib: The Swiss Army Knife In AML Therapy

Kura Oncology's lead candidate, ziftomenib, shows dual-functionality in treating NPM1-mutant AML and overcoming resistance mutations. Company's financials robust with $477M in liquid assets, offsetting a manageable monthly cash burn of $10.2M, providing a 46.8-month cash runway. Given the clinical promise of ziftomenib and strong financial footing, the stock presents an attractive risk-to-reward profile; "Buy" recommendation.

10:41 28 Mar 2024 KURA

Kura Oncology, Inc. (KURA) Q2 2023 Earnings Call Transcript

Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President, Investor Relations & Corporate Communications Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President, Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Roger Song - Jefferies Peter Lawson - Barclays Li Watsek - Cantor Bijan Mekoba - Stifel Julian Harrison - BTIG Reni Benjamin - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Q2 2023 Kura Oncology, Inc. Earnings Conference Call. At this time, all lines are in listen-only mode.

07:00 28 Mar 2024 KURA

7 Best Cancer Stocks to Invest in Now

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which have limited cure and treatment options.

KURA Financial details

Company Rating
Neutral
Market Cap
1.63B
Income
-149.56M
Revenue
1.27M
Book val./share
5.14
Cash/share
5.48
Dividend
-
Dividend %
-
Employees
142
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-8.2
Forward P/E
-8.97
PEG
-3.6929516944438E+15
P/S
-
P/B
2.67
P/C
3.95
P/FCF
-9.42
Quick Ratio
16.44
Current Ratio
16.71
Debt / Equity
0.03
LT Debt / Equity
0.02
-
-
EPS (TTM)
-2.03
EPS next Y
-2.41
EPS next Q
-0.55
EPS this Y
2.46%
EPS next Y
18.72%
EPS next 5Y
-111.61%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
10%
-
-
-
-
SMA20
-
SMA50
40%
SMA100
162.5%
Inst Own
79.55%
Inst Trans
0.73%
ROA
-30%
ROE
41%
ROC
-0.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
76.14M
Shs Float
63.54M
-
-
-
-
Target Price
26
52W Range
7.41-24.17
52W High
-9.92%
52W Low
+208.86%
RSI
52
Rel Volume
0.11
Avg Volume
1.47M
Volume
167.29K
Perf Week
-1.46%
Perf Month
5.41%
Perf Quarter
133.73%
Perf Half Y
152.28%
-
-
-
-
Beta
0.856
-
-
Volatility
0.35%, 0.9%
Prev Close
2.13%
Price
21.62
Change
5.77%

KURA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.51-1.68-1.96-2.03-2.08
Operating cash flow per share
-1.31-1.32-1.58-1.64-1.7
Free cash flow per share
-1.31-1.36-1.59-1.65-1.71
Cash per share
5.6511.937.816.545.79
Book value per share
-5.08-5.7-6.53-8.495.43
Tangible book value per share
5.2211.517.646.275.43
Share holders equity per share
-5.08-5.7-6.53-8.495.43
Interest debt per share
0.190.290.110.210.17
Market cap
576.76M1.73B928.93M831.35M1.05B
Enterprise value
558.12M1.42B845.13M793.57M1.03B
P/E ratio
-9.13-19.38-7.15-6.11-6.9
Price to sales ratio
00000
POCF ratio
-10.53-24.82-8.88-7.55-8.44
PFCF ratio
-10.53-24.08-8.79-7.51-8.42
P/B Ratio
-2.71-5.73-2.15-1.462.65
PTB ratio
-2.71-5.73-2.15-1.462.65
EV to sales
00000
Enterprise value over EBITDA
-8.27-15.48-6.44-5.67-6.26
EV to operating cash flow
-10.19-20.38-8.08-7.21-8.27
EV to free cash flow
-10.19-19.76-8-7.17-8.26
Earnings yield
-0.11-0.05-0.14-0.16-0.14
Free cash flow yield
-0.09-0.04-0.11-0.13-0.12
Debt to equity
-0.04-0.05-0.02-0.020.03
Debt to assets
0.030.020.010.030.02
Net debt to EBITDA
0.283.380.640.270.12
Current ratio
15.3924.4923.2618.5612.26
Interest coverage
-116.34-159.33-318.4-614.08-107.04
Income quality
0.870.780.80.810.82
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.030.010.010
Capex to revenue
00000
Capex to depreciation
0-11.19-2.06-0.82-0.2
Stock based compensation to revenue
00000
Graham number
13.1114.716.9519.715.95
ROIC
0.330.330.310.26-0.4
Return on tangible assets
-0.26-0.14-0.24-0.3-0.34
Graham Net
5.111.257.3965.11
Working capital
224.04M611.27M499.83M422.37M397.22M
Tangible asset value
218.78M610.91M506.61M420.28M397.27M
Net current asset value
216.41M600.99M494.85M410.4M380.82M
Invested capital
-0.04-0.05-0.02-0.020.03
Average receivables
127K15K001.4M
Average payables
3.82M3.14M2.99M2.38M1.92M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
05.18K2.12K737.21988.81
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00.070.170.50.37
Inventory turnover
00000
ROE
0.30.30.30.24-0.38
Capex per share
0-0.04-0.02-0.010

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.02
Net income per share
-0.49-0.45-0.53-0.5-0.55
Operating cash flow per share
-0.39-0.52-0.37-0.38-0.44
Free cash flow per share
-0.39-0.52-0.37-0.38-0.44
Cash per share
6.465.936.835.865.48
Book value per share
-8.39-8.81-9.175.575.14
Tangible book value per share
6.25.786.935.575.14
Share holders equity per share
-8.39-8.81-9.175.575.14
Interest debt per share
0.210.20.180.230.15
Market cap
841.16M836.57M738.43M704.44M1.11B
Enterprise value
803.38M823.05M702.35M693.12M1.09B
P/E ratio
-6.31-6.75-4.97-4.56-6.5
Price to sales ratio
0000875.67
POCF ratio
-31.71-23.32-28.83-24.27-32.42
PFCF ratio
-31.69-23.3-28.72-24.25-32.4
P/B Ratio
-1.48-1.39-1.151.642.8
PTB ratio
-1.48-1.39-1.151.642.8
EV to sales
0000859.83
Enterprise value over EBITDA
-22.85-22.51-17.56-18.25-23.46
EV to operating cash flow
-30.28-22.94-27.42-23.88-31.83
EV to free cash flow
-30.27-22.92-27.32-23.86-31.81
Earnings yield
-0.04-0.04-0.05-0.05-0.04
Free cash flow yield
-0.03-0.04-0.03-0.04-0.03
Debt to equity
-0.02-0.02-0.020.040.03
Debt to assets
0.030.030.030.040.02
Net debt to EBITDA
1.070.370.90.30.43
Current ratio
18.5621.6519.9616.7112.26
Interest coverage
-154.42-101.02103.37-95.55-118.69
Income quality
0.81.050.690.750.8
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000011.2
Research and developement to revenue
000025.62
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
0000-0.01
Capex to depreciation
-0.06-0.17-0.45-0.09-0.07
Stock based compensation to revenue
00005.64
Graham number
9.649.4810.487.918
ROIC
0.060.060.06-0.09-0.12
Return on tangible assets
-0.07-0.07-0.08-0.08-0.1
Graham Net
5.935.486.675.294.84
Working capital
422.37M397.22M453.08M432.39M397.22M
Tangible asset value
420.28M395.18M483.58M429.94M397.27M
Net current asset value
410.4M385.66M465.82M416.08M380.82M
Invested capital
-0.02-0.02-0.020.040.03
Average receivables
00001.4M
Average payables
1.64M2.41M2.81M2.05M2.03M
Average inventory
00000
Days sales outstanding
0000198.43
Days payables outstanding
669.761.44K987.46734.17967.29
Days of inventory on hand
00000
Receivables turnover
00000.45
Payables turnover
0.130.060.090.120.09
Inventory turnover
00000
ROE
0.060.050.06-0.09-0.11
Capex per share
00000

KURA Frequently Asked Questions

What is Kura Oncology, Inc. stock symbol ?

Kura Oncology, Inc. is a US stock , located in San diego of Ca and trading under the symbol KURA

Is Kura Oncology, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $26. The lowest prediction is $26 and the highest is $26

What is KURA stock prediction ?

What is Kura Oncology, Inc. stock quote today ?

Kura Oncology, Inc. stock price is $21.62 today.

Is Kura Oncology, Inc. stock public?

Yes, Kura Oncology, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap